Regeneron Revenue Jumps 36% as Key Drugs Post Gains
The company reported higher quarterly revenue and earnings, expanded its Sanofi alliance, and raised parts of its 2026 financial outlook.
Makkler Newsroom · Oct 30, 09:10 PM · 1 min read
Regeneron Pharmaceuticals, Inc. REGN
NASDAQHealth TechnologyUnited States
$955.47+4.28 (+0.45%)
Market closed· · USD · Data may be delayed
- Day's range
- 942.00961.94
- 52-week range
- 591.52991.73
Financial health
– / 5
Analyst view · 30 firms
Buy20 buy · 10 hold · 0 sell
Avg. target $989.00 (+3.5%)
Prices may be delayed and are for informational purposes only - not investment advice.